by Jasmine Batchelor
July 15, 2019
Vice President, Communications and Outreach,
Institute for Clinical and Economic Review (ICER)
Frequently called the nation’s drug pricing watchdog, the Institute for Clinical and Economic Review (ICER) is an independent and non-partisan research organization that analyzes the cost-effectiveness of emerging healthcare interventions and calculates a hypothetical “value-based price benchmark” that would fairly align with each treatment’s ability to improve patients’ lives. David Whitrap oversees ICER’s stakeholder outreach and media relations, raising nationwide awareness of the organization and highlighting opportunities for public and private payers to use ICER’s value assessments to create a more sustainable, high-value pharmacy benefit. Prior to joining ICER, David spent 17 years supporting the strategic communications of US government agencies, healthcare corporations, and other nonprofits. He led external communications for both a biotech company (Vertex Pharmaceuticals) and a pharmacy benefit manager (Express Scripts), and these cross-industry experiences provided David an unusually broad view of the tensions related to US drug pricing, reimbursement throughout the pharmaceutical supply chain, and incentives for biomedical innovation.